Krystal Biotech (KRYS) PT Raised to $35 at Cantor Fitzgerald

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Krystal Biotech (KRYS) PT Raised to $35 at Cantor Fitzgerald

Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103

October 15, 2018 7:45 AM EDT

KB103 is Krystals first "off-the-shelf", topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa.

Results on 2 patients met all primary efficacy (presence of functional COL7 expression, observation of NC1 and NC2 reactive anchoring fibrils and continued expression following repeat administration) and safety endpoints (no adverse events, inflammation or irritation) in topically administered KB103 wounds.

With respect to secondary endpoints topically administered KB103 wounds closed in 2 weeks and continue to stay closed to date.  Topically administered placebo administered wounds took 10 weeks to close in patient 1 and did not completely close throughout the... More